Literature DB >> 28676144

Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection.

Klemens Fheodoroff, Roongroj Bhidayasiri, Luis Jorge Jacinto, Tae Mo Chung, Kailash Bhatia, Therese Landreau, Carlo Colosimo.   

Abstract

Botulinum toxin is a well-established treatment for a number of conditions involving muscle hyperactivity, such as focal dystonia and spastic paresis. However, current injection practice is not standardized and there is a clear need for structured training. An international group of experts in the management of patients with cervical dystonia (CD) and spastic paresis created a steering committee (SC). For each therapeutic area, the SC developed a core slide set on best practice, based on the literature. International sites of expertise were identified for training and courses were designed to include lectures and casebased learning. Where possible, courses received accreditation from the European Union of Medical Specialists (UEMS). Each course was peer reviewed by the SC, the UEMS accreditation board and the attendees themselves (through evaluation questionnaires). Attendees' feedback was shared with the SC and the trainers to tailor future training sessions. From the program launch in 2012 to December 2014, 328 physicians from 34 countries were trained in a total of 58 courses; 67% of the courses focused on spastic paresis and 33% on CD. Of the 225 (69%) physicians who completed feedback forms, 95% rated their course as 'above average/excellent' in meeting the preset learning objectives. Most (90%) physicians declared that attending a course would lead them to change their practice. The development of the 'Ixcellence Network' for continuous medical education in the fields of spastic paresis and CD has provided a novel and interactive way of training physicians with previous experience in botulinum toxin injection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28676144      PMCID: PMC5507152          DOI: 10.11138/fneur/2017.32.2.103

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  23 in total

1.  Continuing medical education and the physician as a learner: guide to the evidence.

Authors:  Paul E Mazmanian; David A Davis
Journal:  JAMA       Date:  2002-09-04       Impact factor: 56.272

Review 2.  Expanding use of botulinum toxin.

Authors:  Roongroj Bhidayasiri; Daniel D Truong
Journal:  J Neurol Sci       Date:  2005-08-15       Impact factor: 3.181

3.  Spasticity or reversible muscle hypertonia?

Authors:  Abdel Magid O Bakheit; Klemens Fheodoroff; Franco Molteni
Journal:  J Rehabil Med       Date:  2011-05       Impact factor: 2.912

4.  Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  David M Simpson; Mark Hallett; Eric J Ashman; Cynthia L Comella; Mark W Green; Gary S Gronseth; Melissa J Armstrong; David Gloss; Sonja Potrebic; Joseph Jankovic; Barbara P Karp; Markus Naumann; Yuen T So; Stuart A Yablon
Journal:  Neurology       Date:  2016-04-18       Impact factor: 9.910

5.  What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.

Authors:  W Poewe; G Deuschl; A Nebe; E Feifel; J Wissel; R Benecke; K R Kessler; A O Ceballos-Baumann; A Ohly; W Oertel; G Künig
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

6.  Is age associated with the development of antibodies against botulinum toxin?

Authors:  M V Aun; T M Chung; K S Santos; L M R Battistella; L V Rizzo; J Kalil; P Giavina-Bianchi
Journal:  Allergol Immunopathol (Madr)       Date:  2012-09-30       Impact factor: 1.667

7.  A statewide model detection and prevention program for geriatric alcoholism and alcohol abuse: increased knowledge among service providers.

Authors:  C L Coogle; N J Osgood; I A Parham
Journal:  Community Ment Health J       Date:  2000-04

8.  Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study.

Authors:  N Hyman; M Barnes; B Bhakta; A Cozens; M Bakheit; B Kreczy-Kleedorfer; W Poewe; J Wissel; P Bain; S Glickman; A Sayer; A Richardson; C Dott
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-06       Impact factor: 10.154

9.  The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey.

Authors:  Abdel Magid Bakheit; Benjamin Zakine; Pascal Maisonobe; Claire Aymard; Klemens Fhedoroff; Harold Hefter; Jorge Jacinto; Wolfgang H Jost; Franco Molteni; Henk Stam; Lynne Turner-Stokes; Jorg Wissel
Journal:  Int J Rehabil Res       Date:  2010-09       Impact factor: 1.479

10.  Elimination of dysphagia using ultrasound guidance for botulinum toxin injections in cervical dystonia.

Authors:  Justin S Hong; Geeta G Sathe; Christian Niyonkuru; Michael C Munin
Journal:  Muscle Nerve       Date:  2012-10       Impact factor: 3.217

View more
  2 in total

1.  Physicians' Practice of the Non-Cosmetic Uses of Botulinum Toxin: A Cross-Sectional Study in Saudi Arabia.

Authors:  Sarah A Alzarah; Huda Alabasi; Lujain Alanazi; Munirah Aldawsari; Etedal Aldawsari; Shazia Iqbal
Journal:  Cureus       Date:  2022-01-17

2.  Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studies.

Authors:  Vijay P Misra; Richard M Trosch; Pascal Maisonobe; Savary Om
Journal:  J Clin Mov Disord       Date:  2018-07-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.